White Paper Author Matthew Abrahms Agilent Technologies, Inc. Abstract Following the legalization of hemp in the 2018 Farm Bill, the number of hemp-derived products has dramatically increased. Laboratories that inspect the quality and safety of these products are now required to comply with the Food and Drug Administration (FDA) current Good Manufacturing Practices (cGMP). Even facilities that manufacture Cannabidiol (CBD) products should anticipate eventual FDA regulations. For companies new to this process, this landscape can seem difficult to navigate. To assist testing facilities, this white paper has been created to introduce Agilent’s compliance recommendations for the industry. These recommendations are based on FDA cGMP requirements for dietary supplements and Agilent expe

Join for free to read